Total raised
$136.9M
Last: PIPE 2025-02
Stage
Public
Founded
2003
Headcount
258
HQ
Haifa
Sector
Health Tech & Life Sciences
About
Pluri creates cell-based products for commercial use and aims to promote global wellbeing and sustainability. The company's technology platform, a patented and validated 3D cell expansion system, advances novel cell-based solutions for a range of initiatives, from medicine and climate change to food scarcity and animal cruelty. Pluri's method is accurate, scalable, cost effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food technology and aims to establish partnerships that leverage the company's 3D cell-based technology in additional industries that require effective, mass cell production.
Funding history · 7 rounds · $136.9M total
2025-02
PIPE
$3.5M
2025-01
PIPE
$6.5M
2021-02
PIPE
$30.0M
2020-04
Debt Financing
$54.0M
2019-04
PIPE
$20.0M
2017-01
PIPE
$15.0M
2016-10
PIPE
$30.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Agriculture & FoodCropsHealthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
orthopedicsinflammatory-diseasespulmonarybiological-therapyregenerative-medicinestem-cellscell-therapybioprocesscardiovascularpharmaceuticals3d-technologyspace-techpharma-companiespatients